Tumor vaccines are a promising avenue in cancer immunotherapy.Despite the progress in targeting specific immune epitopes,tumor cells lacking these epitopes can evade the treatment.Here,we aimed to construct an efficie...Tumor vaccines are a promising avenue in cancer immunotherapy.Despite the progress in targeting specific immune epitopes,tumor cells lacking these epitopes can evade the treatment.Here,we aimed to construct an efficient in situ tumor vaccine called Vac-SM,utilizing shikonin(SKN)to induce immunogenic cell death(ICD)and Mycobacterium smegmatis as an immune adjuvant to enhance in situ tumor vaccine efficacy.SKN showed a dose-dependent and time-dependent cytotoxic effect on the tumor cell line and induced ICD in tumor cells as evidenced by the CCK-8 assay and the detection of the expression of relevant indicators,respectively.Compared with the control group,the in situ Vac-SM injection in mouse subcutaneous metastatic tumors significantly inhibited tumor growth and distant tumor metastasis,while also improving survival rates.Mycobacterium smegmatis effectively induced maturation and activation of bone marrow-derived dendritic cells(DCs),and in vivo tumor-draining lymph nodes showed an increased maturation of DCs and a higher proportion of effector memory T-cell subsets with the Vac-SM treatment,based on flow cytometry analysis results.Collectively,the Vac-SM vaccine effectively induces ICD,improves antigen presentation by DCs,activates a specific systemic antitumor T-cell immune response,exhibits a favorable safety profile,and holds the promise for clinical translation for local tumor immunotherapy.展开更多
Objective:To investigate the effect of shikonin on the proliferation, apoptosis and extracellular matrix (ECM) of human mesangial cells (MC). Methods: MC was cultured in vitro with different concentrations of glucose ...Objective:To investigate the effect of shikonin on the proliferation, apoptosis and extracellular matrix (ECM) of human mesangial cells (MC). Methods: MC was cultured in vitro with different concentrations of glucose (30, 50, 80 mmol/L). The cell growth was observed by using MTT method and apoptosis by using an aunexin-V-Fluos. Immunohistochemical studies for Laminin (LN), Fibronectin (FN) and type Ⅳ Collagens (Col Ⅳ) were measured. Results: Shikonin inhibited their growth (P<0.05) and apoptosis in the glycated cultured cells. Shikonin 0.05 mmol/L significantly reduced the secretion of LN, FN and Col Ⅳ from MC (P<0.05) cultured in 30, 50 and 80 mmol/L glucose. Conclusion: Shikonin could prevent or treat diabetic nephropathy (DN) and glomerulosclerosis (GS).展开更多
背景:研究表明,紫草素具有促进骨缺损修复、治疗骨质疏松的作用。目的:总结紫草素及其衍生物在口腔软硬组织再生中的应用潜力方法:检索PubMed、Web of Science、万方、中国知网、维普数据库2002-2023年收录的相关文献,中文检索词为“紫...背景:研究表明,紫草素具有促进骨缺损修复、治疗骨质疏松的作用。目的:总结紫草素及其衍生物在口腔软硬组织再生中的应用潜力方法:检索PubMed、Web of Science、万方、中国知网、维普数据库2002-2023年收录的相关文献,中文检索词为“紫草素,口腔,牙周炎,抗菌,成骨分化,破骨细胞,骨质疏松,毒理学”,英文检索词为“shikonin,oral cavity,periodontitis,antibacterial,bone formation,Osteoclast,osteoporosis,toxicology”。结果与结论:紫草素及其衍生物具有抗炎、抑制牙龈卟啉单胞菌等牙周致病菌、促进牙周创面愈合以及牙槽骨组织再生的生物活性。紫草制剂可以治疗口腔阿弗他溃疡、口腔念珠菌病等口腔黏膜疾病。这些证据表明紫草素及其衍生物在治疗牙周病、防治口腔疾病和促进牙周软硬组织再生方面表现出良好的前景。如何将紫草素与组织工程相结合,从而实现更快的口腔软硬组织愈合还有待研究。展开更多
基金supported by grants from the Natural Science Foundation of Huai'an Science and Technology Bureau(Grant No.HAB202312)the Science and Technology Development Fund of the Affiliated Hospital of Xuzhou Medical University(Grant No.XYFY2021018).
文摘Tumor vaccines are a promising avenue in cancer immunotherapy.Despite the progress in targeting specific immune epitopes,tumor cells lacking these epitopes can evade the treatment.Here,we aimed to construct an efficient in situ tumor vaccine called Vac-SM,utilizing shikonin(SKN)to induce immunogenic cell death(ICD)and Mycobacterium smegmatis as an immune adjuvant to enhance in situ tumor vaccine efficacy.SKN showed a dose-dependent and time-dependent cytotoxic effect on the tumor cell line and induced ICD in tumor cells as evidenced by the CCK-8 assay and the detection of the expression of relevant indicators,respectively.Compared with the control group,the in situ Vac-SM injection in mouse subcutaneous metastatic tumors significantly inhibited tumor growth and distant tumor metastasis,while also improving survival rates.Mycobacterium smegmatis effectively induced maturation and activation of bone marrow-derived dendritic cells(DCs),and in vivo tumor-draining lymph nodes showed an increased maturation of DCs and a higher proportion of effector memory T-cell subsets with the Vac-SM treatment,based on flow cytometry analysis results.Collectively,the Vac-SM vaccine effectively induces ICD,improves antigen presentation by DCs,activates a specific systemic antitumor T-cell immune response,exhibits a favorable safety profile,and holds the promise for clinical translation for local tumor immunotherapy.
文摘Objective:To investigate the effect of shikonin on the proliferation, apoptosis and extracellular matrix (ECM) of human mesangial cells (MC). Methods: MC was cultured in vitro with different concentrations of glucose (30, 50, 80 mmol/L). The cell growth was observed by using MTT method and apoptosis by using an aunexin-V-Fluos. Immunohistochemical studies for Laminin (LN), Fibronectin (FN) and type Ⅳ Collagens (Col Ⅳ) were measured. Results: Shikonin inhibited their growth (P<0.05) and apoptosis in the glycated cultured cells. Shikonin 0.05 mmol/L significantly reduced the secretion of LN, FN and Col Ⅳ from MC (P<0.05) cultured in 30, 50 and 80 mmol/L glucose. Conclusion: Shikonin could prevent or treat diabetic nephropathy (DN) and glomerulosclerosis (GS).
文摘背景:研究表明,紫草素具有促进骨缺损修复、治疗骨质疏松的作用。目的:总结紫草素及其衍生物在口腔软硬组织再生中的应用潜力方法:检索PubMed、Web of Science、万方、中国知网、维普数据库2002-2023年收录的相关文献,中文检索词为“紫草素,口腔,牙周炎,抗菌,成骨分化,破骨细胞,骨质疏松,毒理学”,英文检索词为“shikonin,oral cavity,periodontitis,antibacterial,bone formation,Osteoclast,osteoporosis,toxicology”。结果与结论:紫草素及其衍生物具有抗炎、抑制牙龈卟啉单胞菌等牙周致病菌、促进牙周创面愈合以及牙槽骨组织再生的生物活性。紫草制剂可以治疗口腔阿弗他溃疡、口腔念珠菌病等口腔黏膜疾病。这些证据表明紫草素及其衍生物在治疗牙周病、防治口腔疾病和促进牙周软硬组织再生方面表现出良好的前景。如何将紫草素与组织工程相结合,从而实现更快的口腔软硬组织愈合还有待研究。
